Clinical trial

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

NCT04338321

Drugs and interventions used in this trial

7 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Esketamine 28 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Esketamine 56 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Esketamine 84 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Quetiapine XR 50 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Quetiapine XR 100 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Quetiapine XR 150 mg Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention SSRI/SNRI Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-08-21

PhasePHASE3

Conditions

Depressive Disorder, Majorunresolved

Interventions

Esketamine 28 mgDRUG

Esketamine 56 mgDRUG

Esketamine 84 mgDRUG

Quetiapine XR 50 mgDRUG

Quetiapine XR 100 mgDRUG

Quetiapine XR 150 mgDRUG

SSRI/SNRIDRUG

Sponsors & collaborators

Janssen-Cilag International NVlead sponsor

Mapped research locations

BerlinGermany6 SeoulSouth Korea4 TaipeiTaiwan4 PragueCzechia4 SofiaBulgaria4 CórdobaArgentina4 BudapestHungary3 IstanbulTurkey (Türkiye)3 LisbonPortugal3 ThessalonikiGreece3 HamburgGermany2 ViennaAustria2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04338321 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.